更新于：2024-11-01

Autologous MSCs Therapy(Akan Biosciences)

更新于：2024-11-01

概要

研发状态

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用机制

干细胞替代物

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

膝关节炎

非在研适应症-

原研机构

Akan Biosciences LLC初创企业

在研机构

Akan Biosciences LLC初创企业

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与 Autologous MSCs Therapy(Akan Biosciences) 相关的临床试验

NCT04750252 / Not yet recruiting临床1/2期

An Open Label Study to Evaluate Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.

开始日期2022-08-22

申办/合作机构

Akan Biosciences LLC初创企业

100 项与 Autologous MSCs Therapy(Akan Biosciences) 相关的临床结果

登录后查看更多信息

100 项与 Autologous MSCs Therapy(Akan Biosciences) 相关的转化医学

登录后查看更多信息

100 项与 Autologous MSCs Therapy(Akan Biosciences) 相关的专利（医药）

登录后查看更多信息

项与 Autologous MSCs Therapy(Akan Biosciences) 相关的文献（医药）

2023-07-29·Biomedicines

Effects of Mesenchymal Stem Cell Injection into Healed Myocardial Infarction Scar Border Zone on the Risk of Ventricular Tachycardia.

Article

作者: Park, Eun-Hye ; Seong, EunHwa ; Kim, Jin-Moo ; Choi, Young ; Lee, Eunmi ; Chang, Kiyuk

The scar border zone is a main source of reentry responsible for ischemic ventricular tachycardia (VT). We evaluated the effects of mesenchymal stem cell (MSC) injection into the scar border zone on arrhythmic risks in a post-myocardial infarction (MI) animal model. Rabbit MI models were generated by left descending coronary artery ligation. Surviving rabbits after 4 weeks underwent left thoracotomy and autologous MSCs or phosphate-buffered saline (PBS) was administered to scar border zones in two rabbits in each group. Another rabbit without MI underwent a sham procedure (control). An implantable loop recorder (ILR) was implanted in the left chest wall in all animals. Four weeks after cell injections, ventricular fibrillation was induced in 1/2 rabbit in the PBS group by electrophysiologic study, and no ventricular arrhythmia was induced in the MSC group or control. Spontaneous VT was not detected during ILR analysis in any animal for 4 weeks. Histologic examination showed restoration of connexin 43 (Cx43) expression in the MSC group, which was higher than in the PBS group and comparable to the control. In conclusion, MSC injections into the MI scar border zone did not increase the risk of VT and were associated with favorable Cx43 expression and arrangement.

2023-03-01·Transplantation Proceedings

Autologous Synovial Mesenchymal Stem Cell Transplantation Suppresses Inflammation Caused by Synovial Harvesting and Promotes Healing in a Micro Minipig Repaired Meniscus Model

Article

作者: Nakamura, Kentaro ; Kubota, Rei ; Furuoka, Hideto ; Ozeki, Nobutake ; Kushida, Yoshihisa ; Ohya, Shoji ; Mizuno, Mitsuru ; Sekiya, Ichiro ; Yanada, Shinobu ; Katano, Hisako ; Koga, Hideyuki ; Okada, Takuya ; Endo, Kentaro

PURPOSEAllogeneic synovial mesenchymal stem cells (MSCs) effectively promote meniscus healing in micro minipigs. We investigated the effect of autologous synovial MSC transplantation on meniscus healing in a micro minipig model of meniscus repair showing synovitis after synovial harvesting.MATERIALS AND METHODSSynovium was harvested from the left knee of the micro minipigs after arthrotomy and used to prepare synovial MSCs. The left medial meniscus in the avascular region was injured, repaired, and transplanted with synovial MSCs. First, synovitis was compared after 6 weeks in knees with and without synovial harvesting. Second, the repaired meniscus was compared for the autologous MSC group and the control group (in which synovium was harvested but MSCs were not transplanted) 4 weeks after transplantation.RESULTSSynovitis was more severe in knees subjected to synovium harvesting than in knees not subjected to harvesting. Menisci treated with autologous MSCs showed no red granulation at the tear of the meniscus, but menisci not treated with MSCS showed red granulation. Macroscopic scores, inflammatory cell infiltration scores, and matrix scores assessed by toluidine blue staining were all significantly better in the autologous MSC group than in the control group without MSCs (n = 6).CONCLUSIONAutologous synovial MSC transplantation suppressed the inflammation caused by synovial harvesting in micro minipigs and promoted healing of the repaired meniscus.

2021-11-01·The Lancet Neurology1区 · 医学

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

1区 · 医学

Article

作者: Gimona, Mario ; Nicholas, Richard ; Introna, Martino ; Mallik, Shahrukh ; Strunk, Dirk ; Cellerino, Maria ; Thalamas, Claire ; Courtman, David ; Marrie, Ruth Ann ; Uccelli, Antonio ; Freedman, Mark S. ; Nabavi, Seyed Massood ; Freedman, Mark S ; Le Blanc, Katarina ; Ramo Tello, Cristina ; Miller, David ; Sensebe, Luc ; Marriot, James ; Szwajcer, David ; Radue, Ernst ; Orengo, Giovanni ; Dazzi, Francesco ; Allan, David ; Wuerfel, Jens Thomas ; Sellner, Johann ; Inglese, Matilde ; Ali, Rehiana ; Muraro, Paolo A. ; Capelli, Chiara ; Blinkenberg, Morten ; Battaglia, Mario Alberto ; Laroni, Alice ; Berry, Isabelle ; Bonetti, Bruno ; Clanet, Michel ; Furlan, Roberto ; Fernandez, Oscar ; Iacobaeus, Ellen ; Soelberg Sorensen, Per ; Karimi, Shahedeh ; Marriott, James ; Oliveri, Roberto S ; Izquierdo, Guillermo ; Sorensen, Per Soelberg ; Cencioni, Maria Teresa ; Marley, Stephen ; Schiavetti, Irene ; Arab, Leila ; Comi, Giancarlo ; Aghdami, Naser ; Battaglia, Mario ; Sormani, Maria Pia ; Gualandi, Francesca ; Fischer-Nielsen, Anne ; Guan, Qingdong ; Fernandez, Victoria ; Martino, Gianvito ; Muraro, Paolo ; Loaiza, Sandra ; Pardini, Matteo ; Castellan, Lucio ; Rush, Carolina ; Palanicawande, Renuka ; Radue, Ernst W ; Brundin, Lou ; Agüera-Morales, Eduardo

BACKGROUNDMesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis.METHODSMESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18-50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2-15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2·5-6·5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit.FINDINGSFrom July 16, 2012, until July 31, 2019, 144 patients were randomly assigned to first receive early intravenous infusion of autologous bone marrow-derived MSCs (n=69) or placebo (n=75). MSC treatment did not meet the primary endpoint of efficacy on the total number of GELs accumulated from baseline to week 24 (rate ratio [RR] 0·94, 95% CI 0·58-1·50; p=0·78). 213 adverse events were recorded, similarly distributed between groups (93 cases recorded in 35 [51%] of 69 patients treated first with MSCs vs 120 cases in 42 [56%] of 75 patients infused first with placebo). The most frequent adverse events reported were infection and infestations, with a total of 54 (25%) of 213 adverse events (18 [19%] of 93 in the early-MSC group and 36 [30%] of 120 in the delayed-MSC group). Nine serious adverse events were reported in seven patients treated with placebo versus none in the MSC group. All serious adverse events were considered to be unrelated to the treatment infusion. No deaths were reported during the study.INTERPRETATIONBone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on GELs, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24. Thus, this study does not support the use of bone marrow-derived MSCs to treat active multiple sclerosis. Further studies should address the effect of MSCs on parameters related to tissue repair.FUNDINGFondazione Italiana Sclerosi Multipla (FISM), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the Multiple Sclerosis International Federation (MSIF) for centralised activities. Individual trials participating in the MESEMS network are funded by the following agencies: FISM and Compagnia di San Paolo (Italy); The Danish Multiple Sclerosis Society, The Toyota Foundation, and Danish Blood Donors' Research Foundation (Denmark); the Spanish Health Research Institute Carlos 3 and the Andalusian Public Foundation Progreso y Salud (Spain); the Royan Institute for Stem Cell Biology and Technology (Iran); the Spinal Cord Injury and Tissue Regeneration Centre Salzburg, Paracelsus Medical University, and Salzburg (Austria); the Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon (France); the UK Multiple Sclerosis Society and the UK Stem Cell Foundation (UK); and the Multiple Sclerosis Society of Canada and The Multiple Sclerosis Scientific Research Foundation and Research Manitoba (Canada).

100 项与 Autologous MSCs Therapy(Akan Biosciences) 相关的药物交易

登录后查看更多信息